DDX41 and acute myeloid leukemia: These results suggest that pathogenic DDX41 variants in human familial MDS/AML contribute to disease development through the accumulation of R-loops and DSBs as well as provide incentives to explore ATR inhibition as a therapeutic strategy in these patients.